Genscript Biotech Gestion
Gestion contrôle des critères 3/4
Le PDG Genscript Biotech est Sherry Shao, nommé en Jul2021, a un mandat de 5.08 ans. La rémunération annuelle totale est $ 2.81M, composée du salaire de 14.4% et des bonus 85.6%, y compris les actions et options de la société. détient directement 0.073% des actions de la société, d'une valeur de HK$ 54.65M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.1 ans et 3.4 ans.
Informations clés
Sherry Shao
Directeur général
US$2.8m
Rémunération totale
| Pourcentage du salaire du PDG | 14.43% |
| Durée du mandat du directeur général | 5.1yrs |
| Propriété du PDG | 0.07% |
| Durée moyenne d'occupation des postes de direction | 5.1yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 3.4yrs |
Mises à jour récentes de la gestion
Recent updates
Genscript Biotech Corporation (HKG:1548) Released Earnings Last Week And Analysts Lifted Their Price Target To HK$24.74
It's been a pretty great week for Genscript Biotech Corporation ( HKG:1548 ) shareholders, with its shares surging 15...
1548: AI Drug Discovery Partnership Will Test Elevated Profit Assumptions
Analysts now place Genscript Biotech's fair value at about HK$20.21, compared with the prior HK$17.68, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple. What's in the News for Genscript Biotech GenScript Biotech and Tamarind Bio agreed a partnership that links Tamarind Bio's AI molecular design platform with GenScript's wet lab validation services, creating a connected validation engine for AI enabled drug discovery.1548: New Expression Platform Will Support Future Cell Therapy Upside
Analysts have made a small adjustment to their price target for Genscript Biotech to HK$17.68. This reflects updated views on the company’s fair value, discount rate, revenue growth, profit margin and future P/E assumptions.1548: European mRNA Buildout And Cell Therapy Data Will Support Future Upside
Analysts have made a very small upward adjustment to Genscript Biotech's fair value estimate, moving the target from about HK$17.67 to roughly HK$17.67. They refreshed assumptions around the discount rate, revenue growth, profit margin and future P/E to reflect current views on the business.1548: European mRNA Expansion Will Support Future Upside Potential
Analysts have kept their HK$17.67 price target for Genscript Biotech broadly unchanged, with only slight tweaks to the discount rate and future P/E assumptions shaping this latest narrative update. What's in the News GenScript plans to put amendments to its fourth amended and restated memorandum and articles of association to a shareholder vote at the AGM on June 5, 2026, and proposes adopting a fifth amended and restated version of these governing documents (Key Developments).1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential
Analysts have trimmed their price target for Genscript Biotech to about HK$17.67 from roughly HK$18.56, citing slightly lower fair value estimates and a modestly reduced future P/E assumption, while keeping revenue growth and profit margin expectations broadly unchanged. What's in the News GenScript opened its first European mRNA production site in Delft, the Netherlands, expanding its mRNA platform and reinforcing Europe as a core part of its integrated R&D and production network (Key Developments).1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential
Analysts have slightly adjusted their view on Genscript Biotech, trimming the implied fair value from about HK$18.95 to around HK$18.56 as they fine tune assumptions on revenue growth, profit margin and future P/E levels. What's in the News Genscript opened its first European mRNA production site in Delft, the Netherlands, adding gene design, synthesis, vector engineering, IVT mRNA production, GenCap mRNA capping, UTR optimization and formulation support within a single facility (Key Developments).
Heavy Automation Costs And Legend Exposure Will Slowly Give Way To Healthier Margins
Catalysts About Genscript Biotech Genscript Biotech is a global biotech group focused on gene to protein research tools, biologics CRDMO services and industrial enzyme products. What are the underlying business or industry changes driving this perspective?1548: European mRNA Expansion Will Support Ongoing Upside Potential
Analysts have trimmed their HK$ price target on Genscript Biotech from about HK$22.12 to around HK$18.95, citing updated assumptions for slower revenue growth, a higher profit margin profile, and a lower future P/E multiple in their models. What's in the News GenScript opened its first European mRNA production site in Delft, the Netherlands, expanding its global mRNA platform with end to end capabilities that include gene design, vector engineering, IVT mRNA production, GenCap mRNA capping technology, UTR optimization, and formulation support (Key Developments).1548: Higher Future P/E Assumptions Will Support Ongoing Upside Potential
Analysts have adjusted their HK$ price target for Genscript Biotech to reflect updated views on discount rate, long term profit margins and a higher assumed future P/E multiple. This has resulted in a modest recalibration of fair value rather than a wholesale shift in the investment case.1548: Slightly Lower Future P/E Will Still Support Attractive Upside Potential
Analysts have trimmed their price target on Genscript Biotech to reflect a slightly lower assumed future P/E multiple, while keeping fair value broadly unchanged at about HK$22.12. They cite fine tuning of discount rate and margin assumptions rather than any major shift in the core outlook.1548: Higher Discount Rate Will Still Support Attractive Future Upside Potential
Analysts have trimmed their fair value estimate for Genscript Biotech from $23.52 to $22.12, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Genscript Biotech held an Analyst/Investor Day, giving the market a closer look at its business, capital plans, and the assumptions that feed into analyst models (Key Developments).Unpleasant Surprises Could Be In Store For Genscript Biotech Corporation's (HKG:1548) Shares
With a median price-to-sales (or "P/S") ratio of close to 5.5x in the Life Sciences industry in Hong Kong, you could be...Is Genscript Biotech Corporation (HKG:1548) Trading At A 44% Discount?
Key Insights Genscript Biotech's estimated fair value is HK$30.13 based on 2 Stage Free Cash Flow to Equity Genscript...We Think You Can Look Beyond Genscript Biotech's (HKG:1548) Lackluster Earnings
The market for Genscript Biotech Corporation's ( HKG:1548 ) shares didn't move much after it posted weak earnings...Genscript Biotech (HKG:1548) Has A Pretty Healthy Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Global Demand Rebound Will Drive Life Sciences And CDMO Expansion
Despite a sharp decline in consensus revenue growth forecasts and a substantial jump in future P/E, analysts have raised Genscript Biotech's fair value estimate from HK$21.61 to HK$23.01. What's in the News GenScript Biotech launched a new global brand platform, "Scripting Possibilities," alongside a refreshed visual identity and expanded marketing initiatives to drive growth and strengthen global brand presence.Global Demand Rebound Will Drive Life Sciences And CDMO Expansion
Expansion in global markets, technology upgrades, and industry partnerships are set to drive stronger growth, improved margins, and long-term earnings stability.Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$637m |
| Mar 31 2026 | n/a | n/a | -US$585m |
| Dec 31 2025 | US$3m | US$405k | -US$533m |
| Sep 30 2025 | n/a | n/a | -US$264m |
| Jun 30 2025 | n/a | n/a | US$5m |
| Mar 31 2025 | n/a | n/a | -US$31m |
| Dec 31 2024 | US$4m | US$352k | -US$67m |
| Jun 30 2024 | n/a | n/a | US$419m |
| Mar 31 2024 | n/a | n/a | US$421m |
| Dec 31 2023 | US$2m | US$353k | US$423m |
Rémunération vs marché: La rémunération totale de Sherry ($USD 2.81M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Hong Kong ($USD 961.07K ).
Rémunération et revenus: La rémunération de Sherry a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Sherry Shao (46 yo)
Ms. Weihui Shao, also known as Sherry, is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined t...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Executive Chairman | 11yrs | US$525.00k | 0.016% HK$ 12.4m | |
| CEO & COO | 5.1yrs | US$2.81m | 0.073% HK$ 54.6m | |
| Co-Founder | 24.6yrs | US$803.00k | 0.040% HK$ 29.8m | |
| Co-Founder & Executive Director | 3.7yrs | US$645.00k | pas de données | |
| Chief Strategy Officer & Executive Director | 5.8yrs | US$595.00k | 0.049% HK$ 37.1m | |
| Chief Financial Officer | 1.3yrs | pas de données | pas de données | |
| General Counsel & Chief Compliance Officer | no data | pas de données | pas de données | |
| Chief Marketing & Corporate Communications Officer | no data | pas de données | pas de données | |
| Head of Global Diversity | no data | pas de données | pas de données | |
| Head of Sustainability | no data | pas de données | pas de données | |
| President of GenScript Life Science Group | no data | pas de données | pas de données | |
| CEO of Probio | no data | pas de données | pas de données |
Gestion expérimentée: L'équipe dirigeante de 1548 est chevronnée et expérimentée (5.1 années d'ancienneté moyenne).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Executive Chairman | 11yrs | US$525.00k | 0.016% HK$ 12.4m | |
| Co-Founder | 11.3yrs | US$803.00k | 0.040% HK$ 29.8m | |
| Co-Founder & Executive Director | 4.3yrs | US$645.00k | pas de données | |
| Chief Strategy Officer & Executive Director | 5.8yrs | US$595.00k | 0.049% HK$ 37.1m | |
| Independent Non-executive Director | 1.9yrs | US$70.00k | 0.00030% HK$ 225.9k | |
| Member of Advisory Board | 2.6yrs | pas de données | pas de données | |
| Member of Advisory Board | 6.9yrs | pas de données | pas de données | |
| Independent Non-Executive Director | 1.9yrs | US$100.00k | pas de données | |
| Member of Scientific Advisory Board | 2.4yrs | pas de données | pas de données | |
| Independent Non-Executive Director | 7.8yrs | US$100.00k | 0.00068% HK$ 512.1k | |
| Independent Non-Executive Director | 2.3yrs | US$100.00k | pas de données | |
| Independent Non-Executive Director | 2.3yrs | US$100.00k | pas de données |
Conseil d'administration expérimenté: Les membres du conseil d'administration de 1548 sont considérés comme expérimentés (ancienneté moyenne 3.4 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/23 06:59 |
| Cours de l'action en fin de journée | 2026/08/21 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Genscript Biotech Corporation est couverte par 12 analystes. 7 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Zhu Chen | Citic Securities Co., Ltd. |
| Wai Chak Yuen | Daiwa Securities Co. Ltd. |